{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:29:51Z","timestamp":1793820591285,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005274","name":"North-West University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001342","name":"Department of Science and Technology, Republic of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001343","name":"University of Pretoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.mbs.2026.109806","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:27:46Z","timestamp":1788589666000},"page":"109806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mutant p53 gain-of-function and immune suppression: Mathematical modeling of STING\u2013TBK1\u2013IRF3 axis restoration for enhanced cancer therapy"],"prefix":"10.1016","volume":"402","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9469-2324","authenticated-orcid":false,"given":"Salaheldin","family":"Omer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Ouifki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermane","family":"Mambili-Mamboundou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mbs.2026.109806_bib0001","doi-asserted-by":"crossref","first-page":"21087","DOI":"10.3390\/ijms141021087","article-title":"Cancer development, progression, and therapy: an epigenetic overview","volume":"14","author":"Sarkar","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.mbs.2026.109806_bib0002","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/cdd.2015.53","article-title":"TP53: An oncogene in disguise","volume":"22","author":"Soussi","year":"2015","journal-title":"Cell Death Differ."},{"issue":"6381","key":"10.1016\/j.mbs.2026.109806_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/358015a0","article-title":"p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mbs.2026.109806_bib0004","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/13102818.2008.10817532","article-title":"The role of p53 tumor-suppressor protein in apoptosis and cancerogenesis","volume":"22","author":"Maximov","year":"2008","journal-title":"Biotechnol. Biotechnol. Equip."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3","article-title":"The p53 pathway","volume":"187","author":"Prives","year":"1999","journal-title":"J. Pathol."},{"issue":"34","key":"10.1016\/j.mbs.2026.109806_bib0006","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.25267","article-title":"p53 and metabolism: from mechanism to therapeutics","volume":"9","author":"Simabuco","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.mbs.2026.109806_bib0007","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jcb.30331","article-title":"A comprehensive study of p53 protein","volume":"123","author":"Patil","year":"2022","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.mbs.2026.109806_bib0008","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.mbs.2026.109806_bib0009","series-title":"Seminars in Cancer Biology","first-page":"353","article-title":"TP53 Mutation patterns in breast cancers: searching for clues of environmental carcinogenesis","volume":"11","author":"Olivier","year":"2001"},{"issue":"2","key":"10.1016\/j.mbs.2026.109806_bib0010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ccell.2018.07.004","article-title":"Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion","volume":"34","author":"Schulz-Heddergott","year":"2018","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.mbs.2026.109806_bib0011","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1080\/15384101.2019.1688951","article-title":"Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA","volume":"18","author":"Huang","year":"2019","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0012","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling strength determines proapoptotic functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.mbs.2026.109806_bib0013","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-Dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.mbs.2026.109806_bib0014","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.mbs.2026.109806_bib0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002850050127","article-title":"Modeling immunotherapy of the tumor\u2013immune interaction","volume":"37","author":"Kirschner","year":"1998","journal-title":"J. Math. Biol."},{"issue":"2","key":"10.1016\/j.mbs.2026.109806_bib0016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02460644","article-title":"Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis","volume":"56","author":"Kuznetsov","year":"1994","journal-title":"Bull. Math. Biol."},{"issue":"7265","key":"10.1016\/j.mbs.2026.109806_bib0017","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING Regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.mbs.2026.109806_bib0018","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/emboj.2010.50","article-title":"Viral apoptosis is induced by IRF-3-mediated activation of bax","volume":"29","author":"Chattopadhyay","year":"2010","journal-title":"EMBO J."},{"issue":"7758","key":"10.1016\/j.mbs.2026.109806_bib0019","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41586-019-1228-x","article-title":"A conserved PLPLRT\/SD motif of STING mediates the recruitment and activation of TBK1","volume":"569","author":"Zhao","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mbs.2026.109806_bib0020","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.tranon.2018.07.012","article-title":"Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer","volume":"11","author":"Jiang","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.mbs.2026.109806_bib0021","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.csbj.2019.07.009","article-title":"Correlate the TP53 mutation and the HRAS mutation with immune signatures in head and neck squamous cell cancer","volume":"17","author":"Lyu","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"7","key":"10.1016\/j.mbs.2026.109806_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179726","article-title":"Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors","volume":"12","author":"Siemers","year":"2017","journal-title":"Plos One"},{"issue":"12","key":"10.1016\/j.mbs.2026.109806_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028293","article-title":"miR451 and AMPK mutual antagonism in glioma cell migration and proliferation: a mathematical model","volume":"6","author":"Kim","year":"2011","journal-title":"Plos One"},{"key":"10.1016\/j.mbs.2026.109806_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106938","article-title":"The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer","volume":"270","author":"Busselaar","year":"2024","journal-title":"Immunol. Lett."},{"issue":"8","key":"10.1016\/j.mbs.2026.109806_bib0025","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/cancers16081600","article-title":"Signaling by type I interferons in immune cells: disease consequences","volume":"16","author":"Zannikou","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.mbs.2026.109806_bib0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jtbi.2012.03.024","article-title":"Modeling the inhibition of breast cancer growth by GM-CSF","volume":"303","author":"Szomolay","year":"2012","journal-title":"J. Theor. Biol."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12967-018-1432-8","article-title":"Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach","volume":"16","author":"Eftimie","year":"2018","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 Regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"27","key":"10.1016\/j.mbs.2026.109806_bib0029","doi-asserted-by":"crossref","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 signaling differentially affects T-cell effector functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.mbs.2026.109806_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/17486700802216301","article-title":"Mathematical model creation for cancer chemo-immunotherapy","volume":"10","author":"de Pillis","year":"2009","journal-title":"Comput. Math. Methods Med."},{"issue":"2","key":"10.1016\/j.mbs.2026.109806_bib0031","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1212\/WNL.55.2.322","article-title":"Effect of interferon \u03b2 on human myelin basic protein-specific T-cell lines: comparison of IFN\u03b2-1a and IFN\u03b2-1b","volume":"55","author":"Francis","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mbs.2026.109806_bib0032","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1023\/A:1011974512425","article-title":"Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-\u03b2 (IFN-\u03b2)","volume":"15","author":"Runkel","year":"1998","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0033","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1749-6632.2000.tb06705.x","article-title":"The p53 tumor suppressor gene: from molecular biology to clinical investigation","volume":"910","author":"Soussi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0034","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2006.01.122","article-title":"Regulation of IRF7 through cell type-specific protein stability","volume":"342","author":"Prakash","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mbs.2026.109806_bib0035","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3389\/fmicb.2017.01854","article-title":"Human cytomegalovirus IE2 86\u202fkDa protein induces STING degradation and inhibits cGAMP-mediated IFN-\u03b2 induction","volume":"8","author":"Kim","year":"2017","journal-title":"Front. Microbiol."},{"issue":"10","key":"10.1016\/j.mbs.2026.109806_bib0036","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/10799900050163226","article-title":"Pharmacokinetics and pharmacodynamics of IFN-\u03b21a in healthy volunteers","volume":"20","author":"Buchwalder","year":"2000","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.mbs.2026.109806_bib0037","series-title":"Cell biology by the numbers","author":"Milo","year":"2015"},{"key":"10.1016\/j.mbs.2026.109806_bib0038","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3346\/jkms.1998.13.1.44","article-title":"Increased serum levels of mutant p53 proteins in patients with colorectal cancer","volume":"13","author":"Shim","year":"1998","journal-title":"J. Korean Med. Sci."},{"issue":"214","key":"10.1016\/j.mbs.2026.109806_bib0039","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002521","article-title":"STING Specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway","volume":"5","author":"Tanaka","year":"2012","journal-title":"Sci. Signal."},{"issue":"6","key":"10.1016\/j.mbs.2026.109806_bib0040","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acscentsci.4c01982","article-title":"Discovery of clonixeril as a sub-femtomolar modulator of the human STING receptor","volume":"11","author":"Sparks","year":"2025","journal-title":"ACS Cent. Sci."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0041","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41392-022-01252-z","article-title":"Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.mbs.2026.109806_bib0042","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41419-023-05728-w","article-title":"Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients","volume":"14","author":"Holicek","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mbs.2026.109806_bib0043","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pep.2014.08.010","article-title":"Production and characterization of thirteen human type-I interferon-\u03b1 subtypes","volume":"103","author":"Kuruganti","year":"2014","journal-title":"Protein Expr. Purif."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0044","doi-asserted-by":"crossref","DOI":"10.1038\/srep15774","article-title":"Complex stability and dynamic subunit interchange modulates the disparate activities of the yeast moonlighting proteins hal3 and vhs3","volume":"5","author":"Abrie","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0045","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1038\/s41467-025-60221-6","article-title":"High mobility group A1 (HMGA1) promotes esophageal squamous cell carcinoma progression by inhibiting STING-mediated anti-tumor immunity","volume":"16","author":"He","year":"2025","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.mbs.2026.109806_bib0046","first-page":"623","article-title":"Specific binding of human alpha interferon to high-affinity cell-surface binding sites on peripheral blood mononuclear cells","volume":"113","author":"Dooley","year":"1989","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.mbs.2026.109806_bib0047","unstructured":"I. Sino Biological, Recombinant Human IFN-\u03b2 Protein (Catalog No. 10704-HNAS): Product Information and Specifications, 2024, Accessed: 2026, https:\/\/www.sinobiological.com\/recombinant-proteins\/human-ifn-beta-10704-hnas."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0048","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","article-title":"A methodology for performing global uncertainty and sensitivity analysis in systems biology","volume":"254","author":"Marino","year":"2008","journal-title":"J. Theor. Biol."},{"issue":"11","key":"10.1016\/j.mbs.2026.109806_bib0049","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.mbs.2026.109806_bib0050","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/MCB.18.5.2986","article-title":"Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation","volume":"18","author":"Lin","year":"1998","journal-title":"Mol. Cell. Biol."},{"issue":"10","key":"10.1016\/j.mbs.2026.109806_bib0051","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.mbs.2026.109806_bib0052","article-title":"TBK1 is paradoxical in tumor development: a focus on the pathway mediating IFN-I expression","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mbs.2026.109806_bib0053","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.mbs.2026.109806_bib0054","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556426001963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556426001963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:08:58Z","timestamp":1793819338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025556426001963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":54,"alternative-id":["S0025556426001963"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2026.109806","relation":{},"ISSN":["0025-5564"],"issn-type":[{"value":"0025-5564","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutant p53 gain-of-function and immune suppression: Mathematical modeling of STING\u2013TBK1\u2013IRF3 axis restoration for enhanced cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2026.109806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109806"}}